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Acetate-free biofiltration
bicarbonate balance 41 :S-184
bicarbonate kinetics (abst) 761
efficacy, tolerance of 41:S-188
phosphate removal, Mg/Ca balance (abst) 755
Acid-base balance
correction by dialysis 41:S-179
transport, RCCT-28A kidney cell line 173
Acute renal failure
cardiovascular stability, CAVHF, CAVHD 41 :S-245
cyclosporine, transplantation 1058
high bleeding risk patients 41:S-237
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antagonist, hypertension, Na excretion, (abst) 967
cAMP system in human glomeruli 928
ADH-resistant transfected LLC-PK1 cells 1286
Adsorption of factor D by polyacrylonitrile 903
Adynamic bone disease, aluminum toxicity (abst) 754
Albuminuria
anti-GBM nephritis, passive 824
anti-GBM nephritis (abst) 968
Allografts
failed, RF management outcome 41 :S-36
monitoring with NMR urinalysis 234
rejection, clinical/histological aspects (abst) 1188
rejection, EC, T lymphocytes 39:S-124
rejection, T cell analysis 39:S-133
a-enolase, ANCA-positive vasculitis 675
al-antitrypsin deficiency in vasculitis 1329
Alport syndrome
COL4A5 mutations 486, 722, 1116
molecular genetics 38
Aluminum
absorption, with Ci-containing calcium (abst) 1180
kinetics, bicarbonate dialysate 899
post-transplant hemopoiesis 1313
toxicity, adynamic bone disease (abst) 754
Amino acids
CRF progression 933
intra-and extracellular, CAPD, children (abst) 755
Amyloidosis
-2m, HD 41:S-78, 41:S-83, 41:S-88, 41:S-lll
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EPO, CAPD, HD 40:S-lll
uremic cardiopathy 41: S-70
Angiogenesis, basement membrane synthesis 147
Angiotensin converting enzyme (ACE) inhibition
Ca antagonist, CsA, antihypertensive therapy 419
calcium antagonists, renal injury 808
nondiabetic renal disease (abst) 967
Angiotensin I
CsA, renin, gene expression 615
Angiotensin II
blockade, glomerular permselectivity 346
early growth response genes 601
modulates proximal tubular cells 39:S-lOO
receptor, PCR localization 1251
somatostatin, MC, glomerular filtration 324
type 1 receptor mRNA, intrarenal localization 1229
Anti-aldosterone drugs, Bartter's syndrome (abst) 756
Anti-ANP antibodies, post-nephrectomy natriuresis .... 1260
Anti-glomerular basement membrane nephritis
albuminuria 824
albuminuria (abst) 968
Anti-myeloperoxidase antibodies, vasculitis (abst) 763
Anti-neutrophil cytoplasmic antibodies (ANCA)
GN, in situ cytokine production 682
GN, silica exposure (abst) 759
vasculitis, a-enolase 675
vasculitis, al-antitrypsin deficiency 1329
vasculitis, systemic (abst) 759
vasculitis and nephritis (abst) 971
Wegener's disease (abst) 971
Anti-rejection therapies
CD-8 dependent immunoregulation 39: S-120
Antigenic epitopes, collagen IV, synthetic peptides 94
Antihypertensive therapy
cyclosporine A, ACEI, calcium antagonist 419
renal hemodynamics, proteinuria 1210
renal injury 808
Apolipoproteins
B-lOO in glomeruli 430
LDL receptors in human glomeruli 918
Atherosclerosis, hyperhomocysteinemia, uremia 41 :S-72
ATPase enzymes in furosemide therapy 1015
Atrial natriuretic peptide (ANP)
antibodies, post-nephrectomy natriuresis 1260
extra-natriuretic effects 307
response in dogs receiving diuretics 1236
Automatized peritoneal dialysis
creatinine, /32m (abst) 761
Autosomal-dominant polycystic kidney disease (ADPKD)juvenile, murine mutant 1081
positional cloning, PKD1 39:S-20
in the rat 522
Autosomal-recessive polycystic kidney disease
epithelial hyperplasia, murine (abst) 966
Azathioprine, conversion from cyclosporine (abst) 1190
B
Bacterial adhesins binding to glomerular mesangium 592
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collagen IV,DM 114
glycoprotein, anti-tubular BM nephritis 140
hereditary interstitial nephritis (abst) 1180
by high resolution SEM 334
human neutrophil adhesion/activation 26
matrix molecules in 121
nidogen, ternary complex formation 7
proteoglycans 79
structure/variant forms, perlecan 53
synthesis, angiogenesis 147
13-2 integrins, neutrophils, HD membranes 649
13-2 microglobulin
amyloidosis, dialysis 41:S-78, 4l:S-88, 41:S-111
fragments in AB-amyloid in situ 4l:S-l00
metabolism, dialysis 41 :S-83
peritoneal extraction, CAPD, APD (abst) 761
transport and fluid pyrogen content 41 :S-96
Bicarbonate balance
acetate-free biofiltration 41 :S-184
acetate-free biofiltration (abst) 761
Bicarbonate dialysate, aluminum kinetics 899
Biocompatibility
cardiovascular stability, HD 41: S-230
concept review 41:S-209
fibrinolytic activity, HD 41 :S-213
Biopsy, renal (abst) 1179
Bleeding, risk of
arachidonic acid metabolism, platelets (abst) 1183
coagulation studies, CAPD (abst) 1181
management in ARF 41 :S-237
renal failure, hormone therapy (abst) 1183
Blood pressure
adenosine A1-R antagonist, Na excretion (abst) 967
increase, family history (abst) 757
loss of nocturnal decline, CRF (abst) 757
Blood volume
non-invasive measurement (abst) 969
Bone disease
adynamic, aluminum toxicity (abst) 754
ESRD and 436
HD, calcium/phosphate balance 41:S-174
HD, long-term 41:S-116, 41:S-121, 4l:S-125
HD, mineral metabolism, CAPD 40:S-92
Bone resorption, PTH-induced, cysteine proteases 693
Brain-dead patients, donor kidneys from 1363
Branched-chain amino acids
nephrotic patients (abst) 756
Brush border membranes
Li therapy, Na-cotransporters 1074
C
C3 production, cytokines 39:S-37
C4d complement fragmentation, renal graft loss 1333
C5b-9 and cytokines in HD 41:S-221
"Ca-Sandoz" tablets, aluminum toxicity (abst) 1180
Ca2 oscillations
renal collecting system, Na-free solutions 828
Cachexia in the elderly on dialysis, death by 41 :S-282
Calcitriol
intravenously in hyperparathyroidism 41 :S-125
pulsed therapy, histologic effects, HD (abst) 760
renal osteodystrophy (abst) 754
Calcium
active transport, protein kinase C 295
CRF, hyperparathyroidism, hypertension 700
cytosolic signaling, glucose, MC 585
dialysate concentration, hyperparathyroidism 630
dietary, hypercalciuria 189
directional changes, PTH, uremia 1104
erythrocyte transport, hypercalciuria (abst) 763
kinetics, paired filtration dialysis (abst) 761
magnesium balance, AFB, phosphate removal (abst)... 755
phosphate, OCT, hyperparathyroidism 561
phosphate balance, dialysis 4l:S-174
PTH curve, CRF (abst) 760
PTH curve, HD (abst) 761
Calcium antagonist
converting enzyme inhibitors, renal injury 808
cyclosporine A, ACEI, antihypertensive therapy 419
Calcium channel blockers, renal hypoperfusion, CsA.... 706
Calcium renal stones
hypercalciuria, intracellular pH (abst) 762
Cancer
prostatic, Nephrology Forum 955
renal cell carcinoma, incidence 41 :S-167
transplant patients, incidence (abst) 1187
Carboxy-terminal fragments of PTHrP in RF 1371
Carboxyl-end domains, fibronectin 158
Cardiac function
ARF, hepatic failure, HD 41 :S-245
biocompatibiity, HD 41: S-230
effect of dialysate 41 :S-60
hypertrophy, hemodynamics in ESRD 41: S-42
uremia, anemia, rHuEPO 41:S-70
Catecholamines
phosphate excretion, remnant kidney 1021
CD23, soluble, chronic uremia, dialysis 878
cGMP as marker of fluid status, dialysis 41:S-57
Children
CAPD 40:S-65
CAPD, amino acids (abst) 755
CRF, demographics 41:S-31
eosinophilia, acute cellular rejection (abst) 1189
nephrotic syndrome, clinical aspects (abst) 1187
nephrotic syndrome, histological aspects (abst) 1187
neuroendocrine control of GH in CR! 1042
renovascular disease, Nephrology Forum 493
transplantation, compliance study (abst) 1189
uremia, growth hormone resistance 790
CHIP28 water channel
cDNA isolation in rats (abst) 966
Cholesterol, serum, post-transplant (abst) 1183
Chronic renal failure
carboxy-terminal fragment, PTHrP 1371
children, demographics 41 :S-3 1
dietary protein, hemodynamics 443
erythroid progenitor, IL-3 response (abst) 754
hyperparathyroidism, hypertension, Ca2 700
late referral to dialysis 41:S-170
loss of nocturnal decline of BP (abst) 757
neuroendocrine control of GH secretion 1042
"nondippers" and progression (abst) 763
progression, ketoacids, amino acids 933
PTH, hypocalcemia 771
PTH-calcium curve (abst) 760
Cisplatin uptake, reduced by glycine 1226
Citrate-Ca preparations, Al absorption (abst) 1180
Coagulation studies in CAPD (abst) 1181
Cockroft formula, GFR, ERPF estimates (abst) 969
COL4A5 mutations in Alport syndrome 486, 722, 1116
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Collagen I
fibronectin isoforms, endothelial cell variants 45
giomerular epithelial cell culture 470
Collagen IV
antigenic epitopes, synthetic peptides 94
diabetes mellitus, tubular basement membrane 114
Goodpasture syndrome, auto-antibodies 85
ternary complex, laminin, nidogen 7
Collagenase IV, 92 kDa functional analysis 158
Colony stimulating factor-i, lupus nephritis 1000
Color-Doppler study
ureteral jet in renal disease (abst) 756
Complement activation
C5b-9, cytokines, HD 41:S-221
OKT3 treatment, respiratory side effects 1140
PAN membrane, adsorption of factor D 903
Complement C4d fragment
early renal graft loss 1333
Complement receptor type 1
glomerular EC, isolation from 730
Clq antibodies
glomerular inflammation, SLE (abst) 966
Continuous ambulatory peritoneal dialysis (CAPD)
anemia, EPO, HD 40:S-l11
assessing adequacy of 40:S-28
children 40:S-65
children, amino acids (abst) 755
creatinine, 132m (abst) 761
immuno-effector characteristics 641
intraperitoneal pressure/transport (abst) 969
methicillin-resistant staphylococcus aureus 1357
mineral metabolism, bone disease 40:S-92
morbidity and mortality 40:S-4, 40:S-16
nutrition, adequacy of dialysis 40:S-39
osmotic-induced transport 1339
osteocalcin levels (abst) 758
peritonitis (abst) 1180
plasma cGMP as marker of fluid status 41:S-57
protein catabolic rate (abst) 1181
residual renal function and recovery 40:S-106
Copper, urinary, phosphorus, renal stones (abst) 1182
Cortical collecting system, Na-Ca2 exchange 828
Creatinine
peritoneal extraction, CAPD, APD (abst) 761
Crescentic glomerulonephritis
IL-i receptor antagonist 479
Cryoglobulinemia
essential mixed (abst) 762
monocytes in, nephritis 1150
Cryoglobulins, human IgMK-IgG and GN (abst) 758
Cyclic AMP (cAMP)
adenosine A1 receptor, human glomeruli 928
phosphodiesterase IV, ADH-resistant cells 1286
Cyclophosphamide therapy for SLE (abst) 1184
Cyclosporine
conversion to azathioprine (abst) 1190
prednisolone, OKT3, transplantation (abst) 971
trial in steroid-resistant NS 1377
Cyclosporine A
antihypertensive therapy 419
inhibition of Na/K-ATPase 246
renal hypoperfusion 706
renin, angiotensin I, gene expression 615
Cyclosporine toxicity
localization of vascular dysfunction (abst) 970
transplant ATN 1058
Cysteine proteases, PTH, osteoblast contraction 693
Cytokines
ANCA-positive GN, in situ production 682
C3 production 39:S-37
genes in transplantation 39:S- 129
glomerular cells and cytoskeleton 39: S-32
long-term dialysis, cellular immunity 41: S-i 35
mesangial cells 39:S-26
mesangial cells, glomerular injury 39:S-65
mesangial cells, lectins 39:S-4l
production across the membrane 41 :S-205
production in HD, C5b-9 generation 41 :S-22l
Cytoskeleton
glomerular cells 39:S-32
role in adherence/motility 151
TGF-pl, proximal tubule cells, proteoglycans 575
D
Deafness, sensorineural, Fanconi syndrome (abst) 1187
Demographics
children, CRF 41:S-31
diabetics, dialysis, future trends 41:S-14
diabetics, RF, future trends 41:S-8
dialysis, transplantation, future trends 41 :S-2
elderly, RF, future trends 41 :S-18
ESRD, future trends 41:S-4
Diabetes
incidence of dialysis 4l:S-14
renal hyperfiltration, EDRF 1306
Diabetes Control and Complications Trial (DCCT) 668
Diabetes insipidus




RF therapy, future trends 41 :S-8
tubular basement membrane, collagen IV 114
Diabetic nephropathy, glucose, MC matrix 853
Dialysate
calcium concentration, hyperparathyroidism 630
effect on LV function 41 :S-60
membrane pyrogen permeability 41 :S- 195
osmolarity, CAPD 1339
ultrafiltration and endotoxin removal 41: S-201
with and without glucose 1086
Dialysis
acid-base correction 41 :S-l79
/3-2m amyloidosis 4l:S-78, 41:S-88, 41:S-lll
/3-2m fragments, AB-amyloid in situ 41:S-lOO
-2m metabolism 41:S-83
calcium, phosphate balance 41:S-l74
cardiovascular findings in 40:S-85
diabetics 40: S-58
diabetics, incidence in 4l:S-14
elderly 40: S-S 1
elderly, death from cachexia 41:S-282
elderly, ethical/socioeconomic aspects 41: S-27
graft stenosis, Gianturco stent 872
late referral to in CRF 41:S-l70
long-term, cellular immunity 41 :S-135
long-term complications, bone 4l:S-116, 4l:S-121
long-term complications, infection 4l:S-l43
osteoarthropathy, dialysis membranes 4l:S-lll
PAN membrane, factor D adsorption 903
renal cell carcinoma, prevalence 4l:S-167
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soluble CD23, uremia 878
sorbent regenerative (REDY) 899
survival analysis 404
Dialyzers
leukocyte trapping, immunodepression (abst) 755
Dietary
calcium, hypercalciuria 189
fish oil, proteinuria, passive Heymann nephritis 359
protein, hemodynamics, CRF 443
protein and G-protein 1068
Diuretics, response to ANP in dogs 1236
Dopamine receptor modulation 197
Doppler study of ureteral jet
in renal disease (abst) 756
E
E-64d attenuates PTH effects 693
Edema, contrasted to uremia, 19th century 1385
Edematous disorders, hypertension, endopeptidase 273
EDRF (NO), diabetic renal hyperfiltration 1306
Eicosanoids in nephrotoxic serum nephritis 1280
Elderly
dialysis, death from cachexia 41 :S-282
dialysis, ethical/socioeconomic aspects 41 :S-27
dialysis therapy 40:S-51
management of RF, future trends 41:S-18
Electrophysiology of nerve conduction
magnetic stimulation, uremia, EPO (abst) 757
End-stage renal disease
cardiac hypertrophy, hemodynamics 41:S-42
demographics/future trends 41 :S-4
hyperkalemia treatment/prevention 1197
lipoprotein heterogeneity 410
modality selection, non-medical factors 40:S-120
osteodystrophy 436
sleep apnea therapy 1134
Endocytosis, receptor-mediated with vasopressin 845
Endopeptidase-24. 11 273
Endothelial cells
f3-2m amyloidosis 41 :S-88
endothelin-1 release and rHuEPO 1010
integrins 61
recognition/differentiation, laminin 20
variants, fibronectin isoforms, collagen I 45
Endothelin




ternary complex formation, basement membrane 7
Epinephrine, renal function, brain-dead patients 1363
Epithelial cells
cultured glomerular, collagen I 470
hyperplasia, murine ARPKD model (abst) 966
T cell interaction, allograft rejection 39: S-124
Erythrocyte as model of kidney tubule cell (abst) 757
Erythroid progenitor
response to IL-3 in CRF (abst) 754
Erythropoietin
anemia, CAPD, HD 40:S-lll
cell production during hypoxic hypoxia 815
CNS effects, uremia, electrophysiology (abst) 757
monocytes inhibit production (abst) 1181
Essential hypertension
adenosine A1-R antagonist, Na excretion (abst) 967
Essential mixed cryoglobulinemia (abst) 762
Exercise tolerance, EPO, HD (abst) 1182
Extracellular fluid
non-invasive measurement (abst) 969
Extracellular matrix
MC, heparin, mesangioproliferative nephntis 369
MC subunits, PDGF-receptor moderates 1027
polycystic kidney disease 101
protein kinase C 109
TXA2, PGI2, regulate gene expression 1219
F
5-lipoxygenase expression in GN 39:S-95
Fanconi syndrome (abst) 1185, 1187
Fatty acids, N-3 in niembranous nephritis 359





end-stage lesions in OS (abst) 968
functional analysis, carboxyl-end domains 158
isoforms, endothelial cell variants, collagen I 45
production, LDL interactions 218
Fish oil, proteinuria, passive Heymann nephntis 359
Flow cytometry
urinary sediment, transplantation (abst) 756
Fluid status
estimating dry weight 41 :S-50
extracellular, non-invasive measurement (abst) 969
plasma cGMP as marker, dialysis 41:S-57
Fluid transport
intraperitoneal pressure, CAPD (abst) 969
Focal glomerulosclerosis, oxidized LDLs 1243
Focal segmental glomerulosclerosis
glomerular hypertension (abst) 966
glomerular hypertrophy, renal failure (abst) 758
lysis of visceral EC (abst) 968




subunits, ureteral obstruction 865
Gene transfer, mammalian kidney 39:S-l 16
Gianturco stent for dialysis graft stenosis 872
Glomerular basement membrane
heparan sulfate proteoglycan 454
idiopathic IgA nephropathy (abst) 970
laminin distribution 73
Glomerular binding of bacterial adhesins 592
Glomerular capillaries after nephrectomy 1049
Glomerular cells and cytoskeleton 39:S-32
Glomerular charge selectivity
IgGl/IgG2 clearance ratio (abst) 968
Glomerular disease
heparan sulfate proteoglycan, GBM 454
tumor necrosis factor-s 39:S-59
Glomerular epithelial cells
culture 470
isolation of complement receptor-i 730
Glomerular filtration
barrier 567
somatostatin, MC, angiotensin II 324
Glomerular filtration rate
accuracy of slope determination (abst) 969
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acute potassium loading (abst) 970
hippurate clearance measurement (abst) 969
serial measurement in infants 893
Glomerular hyperfiltration
prostaglandins, IDDM (abst) 760
Glomerular hypertension in fawn-hooded rats (abst) 966
Glomerular hypertrophy
focal segmental glomeruloscierosis, RF (abst) 758
Glomerular inflammation
Clq antibodies, SLE (abst) 966
Glomerular injury





angiotensin II blockade 346
Glomerulonephritis
ANCA-positive, in situ cytokine production 682
ANCA-positive, silica exposure (abst) 759
crescentic, IL-1R antagonist 479
experimental mesangioproliferative 369
5-lipoxygenase expression 39: S-95
growth factors, Nephrology Forum 252
human IgMK-IgG cryoglobulins (abst) 758
immunogenetic findings 39:S-3
mesangial proliferative, IL-6 39:S-71
mesangiocapillary (abst) 1184
mesangiocapillary type I, structure and function 381
proliferative and PDGF 39:S-86
rapidly progressive (abst) 763




end-stage, fibronectin lesions (abst) 968
focal segmental (abst) 758, 966, 968
growth hormone induced 39:S-90
Glomerulus, adenosine A1 receptor-cAMP system 928
Glucose
dialysate, content of 1086
mesangial cell matrix 853
mesangial cytosolic calcium 585
Glycine, reduces cisplatin uptake 1226
Glycolate assays
serum and urine, hyperoxalurias (abst) 760
Glycosaminoglycans
urinary excretion, renal stones (abst) 1182
Goodpasture syndrome
auto-antibodies, collagen IV 85
autoantigen 135
Growth factor, expression during regeneration 1267
Growth factor-f31
renal tubule cells, proteoglycans 575
Growth hormone
induces glomerulosclerosis 39:S-90
neuroendocrine control in CR1 1042
resistance in uremia 790
Guanine nucleotide regulatory proteins (G-proteins)
bilateral ureteral obstruction 865
protein intake and 1068
H
Head-out water immersion
renal nerve response (abst) 972
Hemodialysis
access problems 40:S-81
adequacy of 40:S-28, 41:S-274
adequacy of (abst) 1186
anemia, EPO, CAPD 40:S-111
C5b-9 and cytokine production 41 :S-22 I
calcitriol pulsed therapy (abst) 760
complications 41 :S-40
complications, infection 41 :S-l43
dialysate and cardiac function 41: S-60
dialy sate withlwithout glucose 1086
dry weight estimation 41 :S-50
exercise training, EPO (abst) 1182
fibrinolytic activity, biocompatibility 41 :S-213
fluid status, non-invasive measurement (abst) 969
future trends 41:S-2, 41:S-296
Gianturco stent for stenosis 872
heparin kinetics 41:S-131
hepatic failure, cardiovascular stability 41 :S-245
hepatitis B vaccine 4l:S-157
hepatitis B viral DNA detection 41 :S- 161
hepatitis C 1353
hepatitis C (abst) 1185
hepatitis C antibodies 41:S-149
hepatitis C virus markers 41 :S- 153
IL-i induction during 39:S-139
IL-1f3, gene expression during 712
IL-6 gene expression 39:S-149
induces neutrophil degranulation 649
late referral to in CRF 41 :S-170
LV function, hypertension, uremia (abst) 759
membranes and platelet activation 41 :S-2l7
mineral metabolism, bone disease 40:S-92
morbidity and mortality 40:S-4, 40:S-16
natural killer cell function 1298
NMR spectroscopy, muscle metabolism 885
nutritional aspects 40:S-39, 41:S-261, 4l:S-268
plasma cGMP as marker of fluid status 41 :S-57
platelet activating factor 39:S- 154
refilling types characterized 41 :S-67
renal cell carcinoma incidence 41:S-167
TNF-a mRNA induction 39:S-144
transplantation 40:S-l0l
vascular access morbidity, US 1091
vitamin supplementation 1319
Hemoglobin, aluminum post-transplant 1313
Hemolytic uremic syndrome
blood group P1 A (abst) 1184





ARF, cardiovascular stability 41 :S-245
Hepatitis B
PCR detection of viral DNA, in dialysis 41:S-l61
vaccine, HLA-linked response 41 :S-157
Hepatitis C
hemodialysis 41:S-149, 41:S-153, 1353
hemodialysis (abst) 1185
Hepatorenal syndrome, Nephrology Forum 737
Hereditary interstitial nephritis (abst) 1180
Hereditary nephropathy (abst) 1185
High resolution scanning electron microscopy (SEM).... 334
Hippurate clearance measurements
Cockroft formula (abst) 969
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animal model (abst) 754
viral genome 1347
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Hypercalciuria
idiopathic, erythrocyte Ca transports (abst) 763
indapamide (abst) 1188
low calcium diet 189
pH regulation, calcium renal stones (abst) 762
X-linked hypophosphatemic rickets, RF (abst) 758
Hypercholesterolemia
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Hyperparathyroidism
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HD, bone complications 41 :S- 116
hypertension, CRF, Ca2 700
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primary adenomatous, tubular dysfunction (abst) 1185
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Hypertension
CRF, hyperparathyroidism, Ca2 700
endopeptidase-24. 11 273
essential, adenosine A-1-R antagonist (abst) 967
family history (abst) 757
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rHuEPO therapy 1010
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IgA binding, rat MC (abst) 967
induced by rat IgA antibodies (abst) 967
MHC gene polymorphism 39:5-9
Immune complexes
IL-6 production, MC 544
renal somatic cells 128
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Immunodeficiency
leukocyte trapping in dialyzers (abst) 755
long-term dialysis, cellular immunity 41:5-135
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Immunogentics in GN 39:5-3
Indapamide for hypercalciuria (abst) 1188
Infants, serial GFR 893
Infection
glomerulopathy related 623
long-term dialysis complication 41:S-143
mycobacterial, transplantation (abst) 1189
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glomerular, Apo and LDL receptors 918
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Interleukin-1 /3
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Interleukin-3
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Interleukin-6
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Interleukin-8
mesangial cell activation 39:S-65
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Interstitial nephritis, hereditary (abst) 1180
Intra-abdominal pressure
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Ischemic acute renal failure, Nephrology Forum 1160
J
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CRF progression 933
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Kidneys from brain-dead patients
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Matrix molecules in basement membrane 121
Medicare ESRD program data 1091
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platelet activation 41 :S-217
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cytokines and 39:S-26
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LDL interactions 218
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